Cognitive and negative symptoms in schizophrenia with L‐Carnosine adjuvant therapy – A randomized double‐blind placebo‐controlled study

Cognitive and negative symptoms in schizophrenia with L‐Carnosine adjuvant therapy – A randomized double‐blind placebo‐controlled study

Abstract The antioxidant L‐Carnosine is reported to improve negative and cognitive symptoms in Schizophrenia. A randomized double‐blind placebo‐controlled study was planned to study the effectiveness of adjuvant L‐Carnosine therapy in patients with Schizophrenia. 100 eligible patients with predomina...

Full description

Bibliographic Details
Main Authors:	Hema Tharoor, Sindhu Maran, Antra K. Chandan, Manikandan Pari, Shruti Rao, Jothilakshmi Durairaj
Format:	Article
Language:	English
Published:	Wiley 2023-04-01
Series:	Pharmacology Research & Perspectives
Subjects:	antioxidant antipsychotics executive function nutraceutical psychopathology supplement
Online Access:	https://doi.org/10.1002/prp2.1074

Similar Items

Birth Order and Psychopathology
by: Ajay Risal, et al.
Published: (2012-01-01)

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study Investigating the Efficacy of a Whole Coffee Cherry Extract and Phosphatidylserine Formulation on Cognitive Performance of Healthy Adults with Self-Perceived Memory Problems
by: Katarina M. Doma, et al.
Published: (2023-03-01)

The Effect of Aspirin on Schizophrenia; A Double Blind Placebo Controlled Study
by: Hamidreza Jamilian, Gevick Hacoupian
Published: (2017-12-01)

Effectiveness of Apigenin, Resveratrol, and Curcumin as Adjuvant Nutraceuticals for Calvarial Bone Defect Healing: An In Vitro and Histological Study on Rats
by: Felice Lorusso, et al.
Published: (2023-02-01)

Risk factors for pneumonia in patients with schizophrenia
by: Takahiro Haga, et al.
Published: (2018-12-01)

Novel Multi-Ingredient Supplement Facilitates Weight Loss and Improves Body Composition in Overweight and Obese Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Joshua P. Nederveen, et al.
Published: (2023-08-01)

Nutraceutical Combinations in Hypercholesterolemia: Evidence from Randomized, Placebo-Controlled Clinical Trials
by: Olga Protic, et al.
Published: (2021-09-01)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
by: Z.B. Dombi, et al.
Published: (2021-04-01)

Executive Functions and Psychopathology Dimensions in Deficit and Non-Deficit Schizophrenia
by: Maksymilian Bielecki, et al.
Published: (2023-03-01)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
by: Christoph U. Correll, et al.
Published: (2022-01-01)

The Relationship Between Level of Education, Cognitive Function and Medication Adherence in Patients with Schizophrenia
by: Zhu X, et al.
Published: (2023-11-01)

The Synergic Effect of a Nutraceutical Supplementation Associated to a Mediterranean Hypocaloric Diet in a Population of Overweight/Obese Adults with NAFLD
by: Martina Chiurazzi, et al.
Published: (2022-11-01)

Wheatgrass extract has chondroprotective and anti-inflammatory effects on porcine cartilage
by: Kate Cridland, et al.
Published: (2023-01-01)

Phytochemical, Proximate and Mineral Composition, Antioxidant and Antidiabetic Properties Evaluation and Comparison of Mistletoe Leaves from Moringa and Kolanut Trees
by: Olugbenga David Oloruntola, et al.
Published: (2022-08-01)

Narrative Review: The FDA’s Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events
by: WeiQi Li, et al.
Published: (2023-03-01)

Children at risk for schizophrenia : a longitudinal perspective /
by: Watt, Norman F.

Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of a Nutraceutical Combination Monacolin K-Free on the Lipid and Inflammatory Profile of Subjects with Hypercholesterolemia
by: Olga Protic, et al.
Published: (2022-07-01)

Chocolate as Carrier to Deliver Bioactive Ingredients: Current Advances and Future Perspectives
by: Paulinna Faccinetto-Beltrán, et al.
Published: (2021-09-01)

Decrease in cognitive performance and increase of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with higher doses of antipsychotics in women with schizophrenia: a cross-sectional study
by: Ilgner Justa Frota, et al.
Published: (2023-08-01)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
by: Isabella Costamagna, et al.
Published: (2021-01-01)

Laterality of cognitive dysfunction in schizophrenia: A cross-sectional study
by: Kanchan Pant, et al.
Published: (2023-01-01)

Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence
by: Riccardo Bortoletto, et al.
Published: (2023-07-01)

Weight Gain, Mental Symptoms and Self-Esteem in Patients with Schizophrenia
by: Sevde Öner, et al.
Published: (2022-12-01)

Evaluation of the Effect of Barberry Root (Berberis Vulgaris) on the Prevention of Metabolic Syndrome Caused by Atypical Antipsychotic Drugs in Patients with Schizophrenia: A Three-Blind Placebo-Controlled Clinical Trial
by: Hamzeh Rostami, et al.
Published: (2023-06-01)

Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
by: Alessandro Colletti, et al.
Published: (2022-11-01)

Effect of nutraceutical supplementation on semen quality in stallions
by: Edgar Díaz Rojas, et al.
Published: (2023-11-01)

Emerging insights of nutraceuticals as anticancer
by: Swati Patni Pant, et al.
Published: (2023-08-01)

An alternative multimodal approach is effective and safe for fibromyalgia
by: J. Freire de Carvalho, et al.
Published: (2022-06-01)

Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
by: Frias I, et al.
Published: (2016-10-01)

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
by: Arrigo F. G. Cicero, et al.
Published: (2018-08-01)

The relationship between combined antipsychotic use and clinical features in schizophrenia spectrum patients treated in inpatient ward: A retrospective study
by: U. Baklaci
Published: (2021-04-01)

Zinc carnosine: Frontiers advances of supplement for cancer therapy
by: Weiwei Tang, et al.
Published: (2022-07-01)

A blinded, placebo‐controlled study on the clinical effects of vitamin E supplementation in dogs with osteoarthritis
by: Casey L. Gordon, et al.
Published: (2023-09-01)

Effect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial
by: Hamide Abbaspour kasgari, et al.
Published: (2019-12-01)

Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: A double-blind randomized trial
by: Victor Nehmi-Filho, et al.
Published: (2023-01-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial
by: L.A Stabell, et al.
Published: (2023-06-01)

The psychopathological trajectories to delusion in Schizophrenia: the affective and schizotypal pathways
by: D. Borrelli, et al.
Published: (2022-06-01)

What does static electricity has to do with schizophrenia?
by: A. Paraschakis
Published: (2021-04-01)

The challenges in schizophrenia treatment in real-life: The uncomfortable truth
by: E. Rancans
Published: (2021-04-01)